These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 21269744)

  • 1. Allogeneic stem cell transplantation for chronic lymphocytic leukemia: lessons to be learned from minimal residual disease studies.
    Böttcher S; Ritgen M; Dreger P
    Blood Rev; 2011 Mar; 25(2):91-6. PubMed ID: 21269744
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantitative MRD monitoring identifies distinct GVL response patterns after allogeneic stem cell transplantation for chronic lymphocytic leukemia: results from the GCLLSG CLL3X trial.
    Ritgen M; Böttcher S; Stilgenbauer S; Bunjes D; Schubert J; Cohen S; Humpe A; Hallek M; Kneba M; Schmitz N; Döhner H; Dreger P;
    Leukemia; 2008 Jul; 22(7):1377-86. PubMed ID: 18418404
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative analysis of minimal residual disease detection using four-color flow cytometry, consensus IgH-PCR, and quantitative IgH PCR in CLL after allogeneic and autologous stem cell transplantation.
    Böttcher S; Ritgen M; Pott C; Brüggemann M; Raff T; Stilgenbauer S; Döhner H; Dreger P; Kneba M
    Leukemia; 2004 Oct; 18(10):1637-45. PubMed ID: 15343348
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Allotransplantation for chronic lymphocytic leukemia.
    Dreger P
    Hematology Am Soc Hematol Educ Program; 2009; ():602-9. PubMed ID: 20008245
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The evolving role of stem cell transplantation in chronic lymphocytic leukemia.
    Dreger P;
    Hematol Oncol Clin North Am; 2013 Apr; 27(2):355-69. PubMed ID: 23561478
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stem cell transplantation in poor-risk chronic lymphocytic leukemia: assessment of post-transplant minimal residual disease using four- and six-color flow cytometry and allele-specific RQ-PCR.
    Itälä M; Huhtinen AR; Juvonen V; Kairisto V; Pelliniemi TT; Penttilä TL; Rauhala A; Tienhaara A; Remes K
    Eur J Haematol; 2008 Aug; 81(2):100-6. PubMed ID: 18410542
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial.
    Dreger P; Döhner H; Ritgen M; Böttcher S; Busch R; Dietrich S; Bunjes D; Cohen S; Schubert J; Hegenbart U; Beelen D; Zeis M; Stadler M; Hasenkamp J; Uharek L; Scheid C; Humpe A; Zenz T; Winkler D; Hallek M; Kneba M; Schmitz N; Stilgenbauer S;
    Blood; 2010 Oct; 116(14):2438-47. PubMed ID: 20595516
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the Cooperative German Transplant Study Group.
    Schetelig J; Thiede C; Bornhauser M; Schwerdtfeger R; Kiehl M; Beyer J; Sayer HG; Kroger N; Hensel M; Scheffold C; Held TK; Hoffken K; Ho AD; Kienast J; Neubauer A; Zander AR; Fauser AA; Ehninger G; Siegert W;
    J Clin Oncol; 2003 Jul; 21(14):2747-53. PubMed ID: 12860954
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Autologous stem cell transplantation for chronic lymphocytic leukemia.
    Dreger P; Brand R; Michallet M
    Semin Hematol; 2007 Oct; 44(4):246-51. PubMed ID: 17961723
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GvL effects in T-prolymphocytic leukemia: evidence from MRD kinetics and TCR repertoire analyses.
    Sellner L; Brüggemann M; Schlitt M; Knecht H; Herrmann D; Reigl T; Krejci A; Bystry V; Darzentas N; Rieger M; Dietrich S; Luft T; Ho AD; Kneba M; Dreger P
    Bone Marrow Transplant; 2017 Apr; 52(4):544-551. PubMed ID: 27941777
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: the ALL-REZ BFM Study Group.
    Bader P; Kreyenberg H; Henze GH; Eckert C; Reising M; Willasch A; Barth A; Borkhardt A; Peters C; Handgretinger R; Sykora KW; Holter W; Kabisch H; Klingebiel T; von Stackelberg A;
    J Clin Oncol; 2009 Jan; 27(3):377-84. PubMed ID: 19064980
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detecting minimal residual disease in patients with chronic lymphocytic leukemia using 8-color flow cytometry protocol in routine hematological practice.
    Stehlíková O; Chovancová J; Tichý B; Krejčí M; Brychtová Y; Panovská A; Francová Skuhrová H; Burčková K; Borský M; Loja T; Mayer J; Pospíšilová S; Doubek M
    Int J Lab Hematol; 2014 Apr; 36(2):165-71. PubMed ID: 24028768
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Allogeneic hematopoietic stem-cell transplantation for chronic lymphocytic leukemia with 17p deletion: a retrospective European Group for Blood and Marrow Transplantation analysis.
    Schetelig J; van Biezen A; Brand R; Caballero D; Martino R; Itala M; García-Marco JA; Volin L; Schmitz N; Schwerdtfeger R; Ganser A; Onida F; Mohr B; Stilgenbauer S; Bornhäuser M; de Witte T; Dreger P
    J Clin Oncol; 2008 Nov; 26(31):5094-100. PubMed ID: 18711173
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Minimal residual disease assessment in chronic lymphocytic leukaemia.
    Sayala HA; Rawstron AC; Hillmen P
    Best Pract Res Clin Haematol; 2007 Sep; 20(3):499-512. PubMed ID: 17707836
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detectable minimal residual disease before allogeneic hematopoietic stem cell transplantation predicts extremely poor prognosis in children with acute lymphoblastic leukemia.
    Sramkova L; Muzikova K; Fronkova E; Krejci O; Sedlacek P; Formankova R; Mejstrikova E; Stary J; Trka J
    Pediatr Blood Cancer; 2007 Jan; 48(1):93-100. PubMed ID: 16521130
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcome of allogeneic stem cell transplantation for B cell chronic lymphocytic leukemia.
    Pavletic ZS; Arrowsmith ER; Bierman PJ; Goodman SA; Vose JM; Tarantolo SR; Stein RS; Bociek G; Greer JP; Wu CD; Kollath JP; Weisenburger DD; Kessinger A; Wolff SN; Armitage JO; Bishop MR
    Bone Marrow Transplant; 2000 Apr; 25(7):717-22. PubMed ID: 10745256
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is MRD eradication a desirable goal in CLL?
    Moreno C; Ritgen M; Rawstron A
    Best Pract Res Clin Haematol; 2010 Mar; 23(1):97-107. PubMed ID: 20620974
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Minimal residual disease in chronic lymphocytic leukaemia: is it ready for primetime?
    Nabhan C; Coutré S; Hillmen P
    Br J Haematol; 2007 Feb; 136(3):379-92. PubMed ID: 17129223
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Graft-versus-leukemia activity may overcome therapeutic resistance of chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene status: implications of minimal residual disease measurement with quantitative PCR.
    Ritgen M; Stilgenbauer S; von Neuhoff N; Humpe A; Brüggemann M; Pott C; Raff T; Kröber A; Bunjes D; Schlenk R; Schmitz N; Döhner H; Kneba M; Dreger P
    Blood; 2004 Oct; 104(8):2600-2. PubMed ID: 15205268
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Autologous and allogeneic stem cell transplantation for chronic lymphocytic leukemia.
    Dreger P; Montserrat E
    Leukemia; 2002 Jun; 16(6):985-92. PubMed ID: 12040430
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.